Iterum (ITRM) says FDA needs more time to review materials in support of NDA for sulopenem etzadroxil/probenecid
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Iterum Therapeutics Plc (NASDAQ: ITRM) disclosed:
On April 8, 2021, Iterum Therapeutics plc (the “Company”) received notice from the U.S. Food and Drug Administration (“FDA”) that it needs more time to review materials that have been provided by the Company in support of the Company’s new drug application (“NDA”) for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible pathogen and therefore, the previously scheduled FDA Antimicrobial Drugs Advisory Committee (the “Panel”) on June 2, 2021 has been postponed. A new date for the Panel review of the Company’s NDA has not yet been confirmed and the Company continues to work closely with the FDA to facilitate its review.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Infinity Pharma (INFI) Misses Q1 EPS by 3c, Revenues Miss
- Amgen (AMGN) Announces New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients
- Palisade Bio (PALI) Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot FDA News
Related EntitiesAdCom, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!